Brian Werneburg Selected Research

Interferon-beta

1/2019

Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Brian Werneburg Research Topics

Disease

3	Major Depressive Disorder (Major Depressive Disorders) 01/2023 - 01/2021
2	Multiple Sclerosis 01/2019 - 09/2006
2	Relapsing-Remitting Multiple Sclerosis 02/2017 - 01/2016
1	Confusion (Bewilderment) 01/2021
1	Pancreatitis 01/2021
1	Postpartum Depression (Post-Natal Depression) 01/2021
1	Injection Site Reaction 02/2017
1	Erectile Dysfunction 03/2012
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 09/2006

Drug/Important Bio-Agent (IBA)

3	zuranoloneIBA 01/2022 - 01/2021
1	3,4-methylenedioxyethamphetamine (MDEA)IBA 01/2023
1	Tuberculin (PPD)IBA 01/2021
1	Interferon-betaIBA 01/2019
1	InterferonsIBA 02/2017
1	Interferon beta-1a FDA Link 01/2016
1	Testosterone (Sustanon)FDA Link 03/2012
1	Protein-Arginine DeiminasesIBA 09/2006
1	Peptides (Polypeptides)IBA 09/2006
1	Proteins (Proteins, Gene)FDA Link 09/2006
1	Myelin Basic ProteinIBA 09/2006
1	Glial Fibrillary Acidic ProteinIBA 09/2006

Therapy/Procedure

1	Therapeutics 01/2019